Flagship explainer
What drives SUTRO BIOPHARMA, INC.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$191M | FY2025 |
| |
| Income before tax | −$191M | FY2025 |
|
| Operating income | −$158M | FY2025 |
|
| $102M | FY2025 |
| |
| Ending assets | $174M | FY2025 |
|
| Beginning assets | $387M | FY2024 |
|
| −$132M | FY2025 |
| |
| $44.6M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0001193125-26-119873